Blog

MIL-OSI Europe: At a Glance – Question time – Animal health: Preventing and preparing for future health crises in agriculture – 17-10-2024

Source: European Parliament

Animal diseases can result in heavy livestock losses and economic costs, and potentially threaten human health. Through the ‘One Health’ approach and the EU4Health programme, the European Commission wants to link animal, human and soil health, biodiversity, climate, sustainable use of pesticides, and disease surveillance and prevention, to ensure prompt action in future health emergencies. The topic is scheduled for question time with the Commission during the October II plenary session.

MIL OSI Europe News –

January 23, 2025
MIL-OSI Europe: MOTION FOR A RESOLUTION on the urgent need to revise the Medical Devices Regulation – B10-0127/2024

Source: European Parliament

B10‑0127/2024

European Parliament resolution on the urgent need to revise the Medical Devices Regulation

(2024/2849(RSP))

The European Parliament,

– having regard to Article 5(3) of the Treaty on European Union,

– having regard to Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC [1] (the Medical Devices Regulation),

– having regard to Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU [2] (the In Vitro Diagnostic Medical Devices Regulation),

– having regard to Rule 136(2) of its Rules of Procedure,

A. whereas public health is and should remain primarily a competence of the Member States;

B. whereas the implementation of the Medical Devices Regulation has triggered many challenges for manufacturers, notified bodies and healthcare providers;

C. whereas the current complex and costly regulatory framework jeopardises the availability and affordability of medical devices for patients;

1. Calls on the Commission to propose a revision of the Medical Devices Regulation and the In Vitro Diagnostic Medical Devices Regulation to address the challenges that have emerged in their implementation;

2. Underlines that the revision of these regulations should take into consideration the views of the stakeholders along the entire value chain;

3. Stresses that this revision should focus on ensuring the timely availability of medical technologies, a more predictable regulatory system and a reduction in the administrative burden for manufacturers, especially small and medium-sized enterprises;

4. Emphasises that this revision should also contribute to increasing the competitiveness of the sector, while ensuring a high level of patient safety;

5. Instructs its President to forward this resolution to the Council, the Commission and the governments and parliaments of the Member States.

MIL OSI Europe News –

January 23, 2025
MIL-OSI Europe: Press release – 2024 Sakharov Prize finalists shortlisted by MEPs

Source: European Parliament

Members of Parliament’s Foreign Affairs and Development committees have chosen the three finalists for the 2024 Sakharov Prize in a vote on Thursday.

Following the secret ballot, MEPs selected the three finalists for the 2024 Sakharov Prize for Freedom of Thought. These are, in alphabetical order:

– Dr Gubad Ibadoghlu, academic and anti-corruption activist in Azerbaijan;

– María Corina Machado, as leader of the democratic forces in Venezuela and President-elect Edmundo González Urrutia, representing all Venezuelans inside and outside the country fighting to restore freedom and democracy;

– “Women Wage Peace” and “Women of the Sun”, Israel/Palestine.

Find the biographies of the candidates and finalists by following this link.

Next steps

The Conference of Presidents (EP President Roberta Metsola and the leaders of the political groups) will choose the 2024 laureate of the Sakharov Prize for Freedom of Thought on Thursday 24 October. The winner(s) will be announced immediately afterwards in the plenary session in Strasbourg.

The award ceremony, which foresees an endowment of EUR 50 000 for the winner(s), will take place during the December plenary session in Strasbourg.

Background

Named after Soviet physicist and political dissident Andrei Sakharov, who agreed to his name being used, the Sakharov Prize for Freedom of Thought is the EU’s highest human rights award.

It has been awarded by Parliament to individuals or organisations every year since 1988, in recognition of their work in one of the following areas: the defence of human rights and fundamental rights, in particular freedom of expression, the safeguarding of minority rights, respect for international law, the development of democracy and the defence of the rule of law.

Many worthy winners have received the award, including Nelson Mandela and Anatoly Marchenko in the first edition, and also dissidents, political leaders, journalists, lawyers, civil society activists, the United Nations and a child activist for the right to education.

Several Sakharov Prize laureates have also won the Nobel Peace Prize, such as Nelson Mandela, Malala Yousafzai, Denis Mukwege and Nadia Mourad.

For a list of previous winners, click here.
In 2023, the Sakharov Prize for Freedom of Thought was awarded to Jina Mahsa Amini and the ‘Woman, Life, Freedom’ movement in Iran.

MIL OSI Europe News –

January 23, 2025
MIL-OSI Europe: MOTION FOR A RESOLUTION on the urgent need to revise the Medical Devices Regulation – B10-0125/2024

Source: European Parliament

B10‑0125/2024

European Parliament resolution on the urgent need to revise the Medical Devices Regulation

(2024/2849(RSP))

The European Parliament,

– having regard to Article 168 of the Treaty on the Functioning of the European Union, which provides that ‘a high level of human health protection shall be ensured in the definition and implementation of all Union policies and activities’,

– having regard to Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC (MDR)[1], and Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU (IVDR)[2],

– having regard to the Commission’s 2023 implementation report on the MDR/IVDR [3],

– having regard to the European Medicines Agency’s 2023 Annual Report and its review on market access and safety concerns for medical devices [4],

– having regard to Rule 136(2) of its Rules of Procedure,

A. whereas medical devices and in vitro diagnostic medical devices play a crucial role in modern healthcare, directly affecting the health, safety and well-being of millions of patients across the EU;

B. whereas the introduction of the MDR and the IVDR was intended to strengthen the regulatory framework for medical devices and in vitro diagnostic medical devices, ensuring higher standards of safety, transparency and clinical performance, while also fostering innovation in the sector;

C. whereas despite these aims, significant challenges have been encountered in implementing the MDR and the IVDR, not only leading to delays but also resulting in failures to achieve certification and approval of medical devices and in vitro diagnostic medical devices, particularly impacting small- and medium-sized enterprises (SMEs), as well as resulting in shortages of medical devices and in vitro diagnostic medical devices, thus restricting patient access to innovative therapeutic and diagnostic technologies;

D. whereas many stakeholders, especially including SMEs, notified bodies and healthcare providers, have reported difficulties in navigating the complex and costly regulatory procedures under the current MDR and IVDR framework, with potential risks posed to the continuous availability of life-saving medical devices and critical in vitro diagnostic tests in Europe as manufacturers reduce their product portfolios and withdraw from the EU;

E. whereas recent scientific and market data point to concerns about shortages of capacity among notified bodies, leading to bottlenecks in the certification process, as well as a lack of clarity around the interpretation of several key provisions of the MDR and the IVDR;

F. whereas the COVID-19 pandemic further exposed vulnerabilities in the EU’s supply chain for medical devices and in vitro diagnostic medical devices, highlighting the need for more flexible and efficient regulatory mechanisms to ensure timely access to essential devices during public health emergencies;

G. whereas given the rapid pace of innovation, including advances in digital health, artificial intelligence and personalised medicine, there is an urgent need to revise the MDR and the IVDR in order to accommodate new technologies and ensure that the regulatory framework remains fit for purpose;

H. whereas practical observations following the adoption of the MDR and the IVDR indicate that significant financial and administrative barriers for orphan and innovative devices stem from the complex procedures of conformity assessment, including obtaining scientific advice, fees required by notified bodies, the extensive and unpredictable duration of the conformity assessment process, and the associated costs;

I. whereas the MDR and the IVDR also present challenges for maintaining equitable access to devices across all of the Member States, with patients in less economically developed regions facing additional delays in accessing new technologies;

1. Calls on the Commission to put forward, in the first hundred days of the new mandate, a proposal for a systematic revision of Medical Devices Regulation (EU) 2017/745 (MDR) and In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 (IVDR);

2. Recognises the significant contributions of the MDR and the IVDR to enhancing the safety and quality of medical devices, but stresses the need for an urgent review of some of its provisions to address the delays and bottlenecks that are currently hampering access to medical technologies; underlines that the review must aim to make full use of the mechanisms in Article 36(3) MDR to adopt implementing acts in order to resolve issues of divergent interpretation and of practical application to streamline the regulatory process, improve transparency and reduce the bureaucratic burden by eliminating any unnecessary administrative work for notified bodies and manufacturers, particularly SMEs, without compromising on patient safety;

3. Stresses the importance of increasing the capacity of notified bodies in order to ensure the timely certification of medical devices and in vitro diagnostic medical devices; urges the Member States and the Commission to implement measures that significantly increase the speed and efficiency of these bodies in order to address the critical demand in the medical device sector;

4. Advocates for the abolition of re-certification for lower-risk products, including Class IIa and certain Class IIb devices, which should continue to be valid subject to appropriate surveillance by the notified body;

5. Asks the Commission also to consider the abolition of re-certification for implantable devices in Class IIb and devices in Class III, provided ongoing compliance with post-market surveillance and periodic safety update reports demonstrate that the devices perform as intended;

6. Asks the Commission also to consider the abolition of repeated re-certification for in-vitro diagnostic medical devices after an initial re-certification after five years, subject to appropriate surveillance by the notified body;

7. Advocates for the creation of transparent, harmonised, maximum durations for procedural steps in conformity assessments by notified bodies, which would create legal certainty for manufacturers regarding the market access procedure and its duration within the EU;

8. Demands the transparency and EU-wide harmonisation of notified bodies’ fees and fee structures, published in a standardised EU dashboard to allow economic operators to compare notified bodies and make informed choices, ensuring that fees remain a fair compensation for the public service provided;

9. Calls for a revision of the qualification criteria for persons responsible for regulatory compliance (PRRCs) in the MDR and the IVDR; recommends that the criteria be changed to allow practical experience and training as an alternative to academic qualifications, thereby ensuring that a broader range of competencies are considered for the qualification of PRRCs;

10. Calls for the regulatory adaptation of the MDR and the IVDR to accommodate new technologies; recognises that the current framework of the MDR and the IVDR does not fully accommodate rapid advancements in medical technology, especially in fields such as digital health, AI-driven diagnostics and personalised medical devices; calls for amendments to the MDR and the IVDR to establish clear and fast-track pathways for the approval of innovative technologies, ensuring their safety and performance; proposes the introduction of a prioritisation procedure for innovative medical devices and in vitro diagnostic medical devices, including a fast-track approval process for breakthrough devices that are potentially life-saving or otherwise significantly improve the standard of care;

11. Calls for clear definitions of ‘orphan device,’ ‘orphan population’ and ‘orphan subpopulation’, as determined by the Medical Device Coordination Group in the MDR and the IVDR, to be given in order to provide legal clarity and facilitate the adoption of harmonised measures across the EU, thereby ensuring a high level of safety, quality and transparency in the granting of market access to critical medical devices and in vitro diagnostic medical devices;

12. Calls for the introduction of simplified rules for niche market (and orphan) medical devices analogous to those in other jurisdictions, such as the US; emphasises the need for less burdensome conformity assessment procedures tailored to medical devices and in vitro diagnostic medical devices serving relatively small markets, such as products for the treatment of children or rare diseases;

13. Urges the creation of a register to monitor and ensure the safety and efficacy of these niche and orphan devices; suggests, further, the creation of EU-wide clinical registries, or the amalgamation of data from current national registries, in order to gather comprehensive clinical data on small patient groups that benefit from the availability of orphan devices; notes that this initiative aims to enhance the overall quality of care and support manufacturers in collecting necessary clinical data, especially in indications where multiple orphan devices are available, allowing for combined treatment data to be evaluated and published regularly; observes that the goal is to assure maximum transparency and safety while allowing a streamlined and less bureaucratic approach for niche and orphan devices;

14. Recognises the disproportionate regulatory burden faced by SMEs, which are responsible for the majority of products in the medical device and in vitro diagnostic medical device sector; highlights that this burden threatens to stifle innovation and reduce competition; urges the Commission to develop specific measures to support SMEs, including the provision of model application documents and forms, financial assistance, regulatory guidance and tailored certification pathways that reduce costs and complexity while maintaining high standards of patient safety; proposes the reduction of conformity assessment costs for SMEs by implementing specific provisions such as a reduction in fees, deferral of the payment of fees and provision of administrative assistance through a central EU contact point;

15. Calls for enhanced flexibility in the regulatory process during public health emergencies; stresses the need for a dynamic regulatory framework capable of a rapid response to public health crises, such as pandemics or unforeseen emergencies; urges the Commission to establish emergency provisions that allow for the temporary streamlining of certification processes for critical medical devices, ensuring that such adjustments do not compromise safety standards, thereby facilitating timely access to essential devices during times of crisis; calls for the Commission, in cooperation with the Health Emergency Preparedness and Response structure, to establish a non-exhaustive list of critical medical devices;

16. Calls for the establishment of a central governance structure or medical device office within the Commission’s Directorate-General for Health to centralise responsibilities and powers in the designation management and surveillance of notified bodies, the harmonisation of administrative practices, the development of guidance on the implementation and application of EU regulations applicable to medical devices and in vitro diagnostic medical devices, and the coordination of the applicability of other EU regulations to medical devices and in vitro diagnostic medical devices with other directorates-general of the Commission;

17. Calls for a stronger and more harmonised post-market surveillance system that makes use of real-world data and patient feedback to identify and address safety issues more rapidly; encourages, therefore, the establishment of a centralised EU database for post-market data as part of the module for vigilance and post-market surveillance of the European Database on Medical Devices that ensures transparency and facilitates cross-border cooperation in monitoring device performance and addressing risks;

18. Calls on the Member States to inform the central governance structure or office of the results of notified body audits and specific instructions issued to notified bodies concerning administrative practices and conformity assessment procedures; highlights the need for this central governance structure or office to coordinate Member States’ market surveillance and vigilance activities in order to enhance the efficiency of market surveillance across the EU;

19. Urges the Commission to strengthen international cooperation on the simplification, assimilation and mutual recognition of national certification processes, in particular with the US Food and Drug Administration;

20. Calls for an appropriate transition period before the implementation of new rules; emphasises the need to set a transition period before the enforcement of new regulations that would allow enough time for manufacturers to prepare and for the necessary institutional infrastructure to be established; notes that this measure ensures that all stakeholders are fully equipped to meet the regulatory requirements without compromising the overarching objectives of the legislation;

21. Instructs its President to forward this resolution to the Council, the Commission and the governments and parliaments of the Member States.

MIL OSI Europe News –

January 23, 2025
MIL-OSI Europe: MOTION FOR A RESOLUTION on the urgent need to revise the Medical Devices Regulation – B10-0124/2024

Source: European Parliament

B10‑0124/2024

European Parliament resolution on the urgent need to revise the Medical Devices Regulation

(2024/2849(RSP))

The European Parliament,

– having regard to the Treaty on the Functioning of the European Union, in particular Article 168 thereof,

– having regard to Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC [1] (the Medical Devices Regulation – MDR),

– having regard to Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU [2] (the In Vitro Diagnostic Medical Devices Regulation – IVDR),

– having regard to Regulation (EU) 2023/607 of the European Parliament and of the Council of 15 March 2023 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices [3],

– having regard to Regulation (EU) 2022/123 of the European Parliament and of the Council of 25 January 2022 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices [4],

– having regard to the Commission’s 2023 report on the implementation of the MDR and the IVDR,

– having regard to Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment [5],

– having regard to Rule 136(2) of its Rules of Procedure,

A. whereas access to quality medical devices and in vitro medical devices is indispensable for patients’ health and for healthcare systems;

B. whereas more than 500 000 different medical devices are marketed in the EU, covering a broad range of products from plasters to x-ray machines, and they are used for diagnosis, prevention, treatment and rehabilitation and, overall, to improve the quality of life of patients and the work of healthcare professionals and carers;

C. whereas large differences still remain in access to medical devices across the EU, leading to healthcare inequalities;

D. whereas the MDR and the IVDR were adopted to strengthen the regulatory framework in response to several scandals involving the use of unsafe medical equipment, such as hip and breast implants; whereas patient safety and quality standards should never be compromised;

E. whereas the deadlines set in the MDR and the IVDR have been extended several times to give more time to device developers and notified bodies, and to avoid shortages of devices;

F. whereas despite these deadline extensions, healthcare professionals have reported shortages of medical devices and in vitro medical devices, especially for paediatric and orphan devices;

G. whereas it is still uncertain exactly which medical devices are at risk of withdrawal and shortages, because of a lack of transparency from notified bodies;

H. whereas the majority of developers of medical devices and in vitro medical devices are small and medium-sized enterprises with limited resources;

I. whereas the process of applying for certification can be burdensome, lengthy and expensive, especially in some Member States;

J. whereas many stakeholders, such as developers, patient organisations and healthcare providers, have reported difficulties in navigating the regulatory framework for medical and in vitro medical devices;

K. whereas increasing numbers of medical devices are supplied by producers in non-EU countries, some of which are autocratic regimes, raising concerns about the protection and possible misuse of personal medical data collected by medical devices;

1. Deplores the shortages of medical devices and the lack of access to certain medical devices in parts of the EU; stresses that access to and quality of healthcare, including medical devices, should not depend on where in the EU a patient is located;

2. Welcomes the increased capacity of notified bodies; invites the Member States and the Commission to assess whether measures can be taken to further improve the speed and efficiency of these notified bodies without jeopardising patient safety;

3. Stresses the need for more transparency, information and guidance from the authorising authorities to manufacturers undergoing the certification process, including information regarding notified body fees and fee structures; underlines that this is already possible under the current regulation;

4. Further stresses the need for greater transparency and better access to information for patients organisations and healthcare professionals from notified bodies and from national authorities;

5. Underlines that product updates or adjustments should not necessarily lead to the need for a full recertification of the product; calls, in this regard, for harmonised guidance to ensure consistency for medical device developers across the EU;

6. Welcomes the non-legislative actions already initiated by the Commission and calls for further actions to be taken to counter shortages and reduce the administrative burdens, where possible;

7. Welcomes the pilot programme by the European Medicines Agency to support manufacturers producing and notified bodies certifying orphan devices in the processes of development and assessment;

8. Notes that post-authorisation market surveillance can be burdensome, and that a more harmonised approach could benefit both developers and the Member States;

9. Recalls that the MDR should be evaluated by 2027 at the latest; stresses, in this regard, the need for a proper evaluation and impact assessment; further stresses that all relevant stakeholders should be part of the evaluation process;

10. Believes that reducing administrative burdens and ensuring access to medical devices throughout the EU should be key considerations in the evaluation of the regulation;

11. Believes that the evaluation should also examine dependency on non-EU countries, including the protection of personal medical data;

12. Emphasises that any new rules or changes to existing rules must come with an appropriate transition period to allow all stakeholders sufficient time to adjust to change;

13. Instructs its President to forward this resolution to the Council, the Commission and the governments and parliaments of the Member States.

MIL OSI Europe News –

January 23, 2025
MIL-OSI Europe: MOTION FOR A RESOLUTION on the urgent need to revise the Medical Devices Regulation – B10-0122/2024

Source: European Parliament

B10‑0122/2024

European Parliament resolution on the urgent need to revise the Medical Devices Regulation

(2024/2849(RSP))

The European Parliament,

– having regard to Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC [1] (Medical Devices Regulation, MDR), and to Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU [2] (IVDR),

– having regard to the Commission statement of 9 October 2024 on the urgent need to revise the Medical Devices Regulation,

– having regard to the proposal for rejection of the Recommendation for second reading on in vitro diagnostic medical devices [3],

– having regard to Rule 136(2) of its Rules of Procedure,

A. whereas the legislation on medical devices and in vitro medical devices was revised in 2017 through the MDR and the IVDR;

B. whereas the new legislative framework of 2017, which replaced the existing directives with regulations, was a reaction to certain events, first and foremost to a company’s marketing non-medical grade silicone gel breast implants in blatant and intentional violation of the regulatory framework; whereas there have been various violations under the new regulatory framework during the so-called pandemic;

C. whereas the regulations have placed a considerable regulatory burden on the producers of medical devices and in vitro medical devices; whereas the MDR and the IVDR have created a considerable administrative burden for regulators; whereas the combined burden has created both a backlog of required certifications within the industry and an administrative bottleneck for issuing such certifications;

D. whereas this backlog has affected the market for medical devices and in vitro medical devices; whereas there is a shortage of certain medical devices and in vitro medical devices; whereas producers’ innovative capacity has been impaired;

E. whereas a prolonged waiting time for such products, shortages and a lack of innovation due to the inability to cope with bureaucratic obstacles harms patients as consumers of medical products; whereas such harm could ultimately result in an unnecessary loss of life;

F. whereas the Commission needs to have finalised an evaluation of the directives by 27 May 2027 under Article 121 MDR and Article 111 IVDR;

1. Considers that both the IVDR and the MDR have created very burdensome bureaucracy, which is neither in the interest of the producers nor in the interest of patients as consumers; suggests that any inappropriate or disproportionate regulatory burden be lifted as soon as possible; underlines that there is now an urgent need for revision of both the IVDR and the MDR;

2. Recalls that as far back as in 2017 a Parliament minority moved to reject the new framework as too excessive a regulatory burden and too expensive for producers of medical devices to comply with; considers that law is good law when it can stand the test of time; recalls that perceived legislative necessity, as so often encountered in real or perceived crises, should not trump the established rules of proper lawmaking to the detriment of the smooth functioning of parliamentary democracy;

3. Notes that proposals have been made to remedy the problems through tertiary legislation, thereby circumventing the ordinary legislative procedure; underlines that the shortcomings of Union secondary legislation cannot be corrected by tertiary-level legislation, as this would ultimately mean substituting Parliament’s lawmaking capacity with executive decrees; warns against the widespread and excessive use of delegated acts as a means of repairing flawed legislation;

4. Calls on the Commission not to make use of the full time frame granted for evaluation of the IVDR and the MDR, but instead to speed up the process as much as possible; notes that the Commission has been called upon to come up with a proposal within a hundred days of the start of the new Commissioners’ term of office;

5. Calls on the Commission to immediately present an amendment to address the glaring shortcomings of current legislation in the first half of 2025, so that businesses, patients as consumers and healthcare authorities can enjoy immediate relief; calls on the Commission to conduct its evaluation, and present a full legislative proposal, as swiftly as possible;

6. Suggests including in its proposal an accelerated certification procedure for innovative medical products, abolishing the re-certification requirement for lower-risk products and abolishing the certification requirement for niche-products;

7. Considers that, as a prerequisite, there is already a strong and functioning civil liability regime in place that protects consumers, allowing certain regulatory requirements to be relaxed;

8. Instructs its President to forward this resolution to the Council, the Commission and the national parliaments of the Member States.

MIL OSI Europe News –

January 23, 2025
MIL-OSI Europe: MOTION FOR A RESOLUTION on the urgent need to revise the Medical Devices Regulation – B10-0126/2024

Source: European Parliament

B10‑0126/2024

European Parliament resolution on the urgent need to revise the Medical Devices Regulation

(2024/2849(RSP))

The European Parliament,

– having regard to the Treaty on the Functioning of the European Union, in particular Article 168 thereof,

– having regard to the Charter of Fundamental Rights of the European Union, in particular Article 35 thereof,

– having regard to Regulation (EU) 2017/745 of the European Parliament and of the Council of 15 December 2021 on medical devices [1] (Medical Devices Regulation),

– having regard to Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices [2] (In Vitro Medical Devices Regulation),

– having regard to Regulation (EU) 2020/561 of the European Parliament and of the Council of 23 April 2020 amending Regulation (EU) 2017/745 on medical devices, as regards the dates of application of certain of its provisions [3],

– having regard to Regulation (EU) 2022/112 of the European Parliament and of the Council of 25 January 2022 amending Regulation (EU) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical devices and the deferred application of conditions for in-house devices [4],

– having regard to Regulation (EU) 2023/607 of the European Parliament and of the Council of 15 March 2023 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices [5],

– having regard to Regulation (EU) 2024/1860 of the European Parliament and of the Council of 13 June 2024 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, the obligation to inform in case of interruption or discontinuation of supply, and transitional provisions for certain in vitro diagnostic medical devices [6],

– having regard to Regulation (EU) 2022/123 of the European Parliament and of the Council of 25 January 2022 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices [7],

– having regard to Rule 136(2) of its Rules of Procedure,

A. whereas access to safe and effective medical devices and in vitro medical devices plays a crucial role in providing high quality treatment and care for patients in the EU;

B. whereas approximately 500 000 different medical devices are available on the EU market, covering a broad range of technologies from contact lenses to pacemakers and serving different purposes, including diagnosis, prevention, treatment, rehabilitation, and improving the quality of life of patients [8];

C. whereas the Medical Devices Regulation (MDR) and the In Vitro Medical Devices Regulation (IVDR) were adopted to strengthen the legal framework and enhance patient safety in response to a number of scandals involving unsafe medical equipment, such as hip- and breast implants, and to reduce the number of obsolete medical devices on the market;

D. whereas incomplete applications with which manufacturers have not provided notified bodies with sufficient scientific evidence and technical detail are among the main reasons for the current delays in issuing CE certificates [9];

E. whereas the implementation deadlines set in the MDR and IVDR were extended several times to increase the capacity of notified bodies and to help the industry to adjust to the new rules in order to avoid shortages of medical devices;

F. whereas the Commission initiated non-legislative actions to support the transition to the MDR and IVDR, focusing in particular on the availability of medical devices on the market, the preparedness of notified bodies, the development of orphan and paediatric devices, SME support and free scientific advice;

G. whereas although there is now an optimal number of notified bodies established under the MDR, issues remain in terms of the inconsistency of decisions, the lack of transparency regarding decisions and limited capacity for post-market surveillance; whereas more notified bodies still need to be established under the IVDR and the consistency and transparency of their decisions enhanced;

H. whereas there is no harmonised mechanism to monitor interruption of supply of devices and whereas the limited requirement for manufacturers to give prior notice about any interruption of supply of certain critical medical devices or in vitro medical devices was only introduced with Regulation (EU) 2024/1860 and will only take effect in January 2025; whereas to ensure patient health protection more transparency provisions linked to supply chain stability are needed so as to understand what types of devices are at serious risk of market withdrawals and shortages;

1. Stresses its continued support for the swift implementation of the MDR and IVDR and underlines that patient safety must never be compromised and that equal access to quality medical devices must be ensured throughout the EU;

2. Regrets the continuing risks of device shortages, notably in the areas of paediatric and orphan diseases, as a result of the suboptimal implementation of the legal framework;

3. Stresses the urgent need for medical device supply chains to be transparent to prevent device shortages and the need for closer cooperation and stricter reporting obligations, including through the Medical Devices Coordination Group (MDCG) and the Executive Steering Group on Shortages of Medical Devices;

4. Underlines that all relevant information on the processes and decisions of notified bodies regarding the certification of medical devices must be in the public domain and accessible to all the relevant stakeholders; in this regard, reiterates the need for a swift roll-out of a comprehensive, fully functional, and user-friendly European database for medical devices (EUDAMED) that provides complete information on all medical devices available on the EU market and adheres to the highest standards of transparency and accessibility of information;

5. Welcomes the fact that the capacity of notified bodies has significantly increased in recent months and urges the Member States and the Commission to ensure a coordinated approach and harmonisation to improve the efficiency and predictability of decisions taken by notified bodies as well as their fee structure;

6. Calls on the Commission to propose specific timeframes for conformity assessments linked to different classes of medical devices, to ensure predictability for developers, and to envisage the possibility of accelerated timelines when devices are linked to health emergencies or where there is robust scientific evidence of an extraordinary benefit for patients in areas of high unmet medical need;

7. Reiterates that any incentives related to orphan medical devices must be based on clear eligibility criteria, be linked to a prudent system that prevents misuse through an artificial ‘orphanisation’ of the devices, and their use must be registered centrally to ensure better evidence generation throughout the EU;

8. Underlines the need for more optimal stakeholder involvement, including within the notified bodies, and calls on the Member States and Commission to ensure that patients and healthcare professionals have access to all relevant documents and decisions;

9. Underlines that product updates or adjustments should not necessarily lead to a need for an entire re-certification of the product, and in this regard calls for tertiary legislation to harmonise such provisions and ensure consistency for developers across the EU;

10. Calls on manufacturers of medical devices to coordinate more closely with national authorities and prioritise patient safety by ensuring the generation of robust evidence and meeting the requirements of the MDR and IVDR without further delay;

11. Welcomes the non-legislative actions already initiated by the Commission and urges more activities particularly vis-à-vis transparency and post-market surveillance; calls on the national competent authorities to significantly strengthen post-market surveillance activities and communication to patient organisations and healthcare professionals and the general public on risks to health or safety associated with marketed devices; calls on the authorities to ensure that manufacturers adhere to strict, clearly established timelines for implementing corrective actions, including prompt communication and follow-up with all potentially affected patients;

12. Reiterates the need for a thorough evaluation and impact assessment of the MDR and IVDR before the potential reopening of the regulations and underlines that all the relevant stakeholders, including patients and healthcare professionals, must be involved in the evaluation process;

13. Underlines that any potential revision of the medical devices framework must first and foremost uphold high patient safety standards, be based on evidence collected in the evaluation and impact assessment and ensure accompanying measures to support the transition;

14. Instructs its President to forward this resolution to the Council, the Commission and the governments and parliaments of the Member States.

MIL OSI Europe News –

January 23, 2025
MIL-OSI Asia-Pac: TONGA’S REAFFIRM ITS COMMITMENT AND UNWAVERING FAITH ON RENEWABLE ENERGY

Source: Tonga Government

Figure 1: Guest of Honours; Crown Prince Tupouto’a (fourth from left), Crown Princess Sinaitakala Tuku’aho (third from left), Princess Halaevalu (front row), Development Partners and the rest of the delegation during the Commissioning the Solar Powered Mini-grid

Niuafo’ou, Tonga 11^th October, 2024 – Crown Prince Tupouto’a ‘Ulukalala, Crown Princess Sinaitakala Tuku’aho and Princess Halaevalu commissioned the Solar Mini-grid system of Niuafo’ou. Minister of MEIDECC, Hon Fekita ‘Utoikamanu, HE Brek Batley, senior delegations from ADB, Tonga Power Limited, MEIDECC and the Prime Minister’s Office accompanied the guests of honor at the commissioning.

Enthusiasm in the eyes of individuals who are granted the opportunity to enhance their access to electricity from limited hours each day to 24 hours per day, seven days a week was a was a significant milestone observed during the Commissioning of the solar mini-grid. The people of Niuafo’ou now have access to 24/7 electricity service generated from Renewable Energy.

“I wish to reaffirm the Government’s commitment and Tonga’s unwavering faith on renewable energy as a key to addressing the single greatest threat to small island developing states – climate change”, said the Honourable Minister during the Commissioning.

This is one of the Government’s ongoing efforts to improve quality and reliability of electricity supply that is generated from renewable energy. It is not just a technical shift from fossil fuels to renewable sources; it is a transformation that touches upon every aspect of Tongan lives especially in such remote communities like Niuafo’ou.

The solar mini-grid was funded under the Tonga Renewable Energy Project (TREP) which was made possible through the kind assistance of the Green Climate Fund (GCF), Asian Development Bank (ADB), Australian Aid, and the Government of Tonga with the support of Tonga Power Limited and the extraordinary efforts of the Principal Contractor, Infratec NZ and its sub-contractors during the installation stage.

Tungua and Moungaone are in progress for the Haapai Islands and the 4 islands in Vavau (Hunga, Otea, Falevai, and Ofu) under the same project.

MIL OSI Asia Pacific News –

January 23, 2025
MIL-OSI United Kingdom: Fostering is Everything

Source: City of Derby

Foster East Midlands, in partnership with CAN Media, is proud to present ‘Everything’ – a powerful new fostering film that highlights how fostering can truly mean everything to those involved. This film was created in collaboration with over 100 local authorities, including Derby City, Derbyshire County Council, Nottingham City, and Nottinghamshire County Council.

‘Everything’ follows foster carer Mike and his family on a journey through time with two of the children they have looked after, who are now adults. A surprise 60^th birthday party for Mike gives Will and Zara a chance to reflect on how being fostered made a difference to their lives, thanking him for everything.

Thanks to footage shot on a genuine old camcorder, we are taken to the 1990s, to see how Will settles into the family. We also jump back to the 2010s, when a young Zara is being taught to play the guitar by Mike, something that comes full circle when she performs a song at the party. Mike’s son Chris is involved throughout, showing the important role the children of foster carers play.

All of the house and garden scenes were filmed in Chilwell, Nottinghamshire, adding a local and authentic touch to the film.

The concluding message of the film is that what you do with your life could forever change someone else’s – encouraging people to foster in order to make that change.

The film was developed with the input and insight of foster carers and people with care experience, was produced by Reel TwentyFive and project managed by public sector media partner CAN.

Project Director for CAN Media, Rachel Brown describes the main message of the film:

Many people don’t realise how common it is for relationships made through fostering to last well beyond the ‘official’ caring role. This has a huge impact on the lives of those who have been fostered, giving them stability and security well into adulthood.

We also wanted to reflect how the children of foster carers make a difference to children when they come into care, helping them to feel part of the family.

Having over 100 councils taking part in the project, the film will reach a very wide audience, encouraging people to find out more and take the steps towards becoming a foster carer.

Fostering with your local council or children’s trust means you can better support local children and young people who need a safe and nurturing home where they can grow and thrive.

Cllr Paul Hezelgrave, Lead Council’s Cabinet Member for Foster East Midlands said:

The ‘Everything’ project has given our fostering service an amazing film that shows the long-term impact fostering can have, with relationships between carers and children lasting well into adulthood.

All councils need to recruit more foster carers, and by collaborating to produce this emotionally powerful film, we will show people how rewarding and life-changing fostering is.

The message is the same for all of us – we need more people to step forward and become foster carers. ‘Everything’ will help us to reach more people in our communities and encourage them to find out more about this really rewarding role.

We are committed to giving vulnerable children and young people we care for the best chance to thrive, which for many of them is with local fostering families.

Sarah Thomas, chief executive of the Fostering Network says:

The Fostering Network has been proud to support the collaborative film projects since ‘Giants’ in 2017. It’s great to see local authority fostering services pooling resources to produce another amazing film. ‘Everything’ will help to amplify their message about the chronic shortage of fostering households, encouraging more people to come forward and foster.

One of the main characters in the film, Chris, shows how important other family members are when it comes to fostering. This is something we champion throughout October, which is Children of Foster Carers Month.

‘Everything’ is the latest in a series of film collaborations that started in 2017 with ‘Giants’, which was supported by a small number of local authorities in the midlands and has now grown into a national project across England, reflecting the need to recruit more foster carers.

Watch the full version of the ‘Everything’ Film on Foster for East Midlands YouTube channel or view the 30 second shortened version.

If you’re interested in becoming a foster carer or want to learn more, visit Foster for East Midlands webpage, email hello@fosterforeastmidlands.org.uk or call 03033 132950

Be inspired and watch the ‘Everything’ foster film

[embedded content]

MIL OSI United Kingdom –

January 23, 2025

MIL-OSI Asia-Pac: Special Campaign 4.0: Department of School Education & Literacy leads the way in cleanliness and sustainability

Source: Government of India (2)

Posted On: 16 OCT 2024 9:30PM by PIB Delhi

Department of School Education & Literacy (DoSE&L), Ministry of Education along with its Autonomous Bodies (ABs) is actively engaged in the on-going Special Campaign 4.0 started from 2^nd October 2024. DOSE&L has issued guidelines to all ABs for effective execution of Special Campaign 4.0. The focus is on cleanliness drives, managing scrap and pending matters, optimizing space and enhancing office aesthetics. These efforts emphasize efficiency, transparency and improved waste management in government functioning.

At the start of the Special Campaign 4.0 preparatory phase, the Department of School Education & Literacy established specific targets and identified key cleanliness sites nationwide to ensure the effective implementation of the campaign’s goals.

S.No.	Category	Targets
1	Number of Files to be Reviewed	61100
2	Number of Files Identified for weeding out	21410
3	Number of e-Files for Review	1367
4	Number of Cleanliness Campaigns to be conducted	32037

Regular meetings are being conducted to closely monitor the progress towards achieving the Ministry’s set targets, ensuring effective implementation and timely completion of the campaign’s objectives. The targets finalized and action in progress as on 14.10.2024 on various parameters is as below:

As of now, 61,382 square feet of space has been reclaimed through the disposal of scrap and redundant materials, generating a revenue of Rs 7,34,941.
Out of 61,100 physical files identified for review, 48206 have been examined. So far, 22,135 files have been marked for weeding, with 10,883 already weeded out.
27450 cleanliness campaigns have been conducted across schools and institutions, actively working towards achieving the Ministry’s targets.

During Special Campaign 4.0, the enthusiastic participation of institutions and schools is setting a powerful example, driving the message of Swachhata forward with inspiration. National Bal Bhawan, through its vibrant exhibits and 3D models at the Swachhta Gallery, is actively engaging children and raising awareness about the importance of sanitation and hygiene, empowering them to take action in keeping their surroundings clean.

Kendriya Vidyalaya schools across the borders, for example, KVS Kathmandu, KVS Moscow etc. are encouraged to adopt sustainable habits, aligning with the broader goals of Swachh Bharat Mission.”Ek Ped Maa Ke Naam” Campaign is being undertaken with great enthusiasm, with active participation of students, teachers, and community members. So far, under Special Campaign 4.0, a total of 8910 saplings have been planted, symbolizing a collective commitment to both cleanliness and environmental sustainability.

*****

MV/AK

(Release ID: 2065624) Visitor Counter : 39

MIL OSI Asia Pacific News –

January 23, 2025

MIL-OSI Asia-Pac: Special Campaign 4.0: Department of School Education & Literacy leads the way in cleanliness and sustainability

Source: Government of India (2)

Posted On: 16 OCT 2024 9:30PM by PIB Delhi

S.No.	Category	Targets
1	Number of Files to be Reviewed	61100
2	Number of Files Identified for weeding out	21410
3	Number of e-Files for Review	1367
4	Number of Cleanliness Campaigns to be conducted	32037

As of now, 61,382 square feet of space has been reclaimed through the disposal of scrap and redundant materials, generating a revenue of Rs 7,34,941.
Out of 61,100 physical files identified for review, 48206 have been examined. So far, 22,135 files have been marked for weeding, with 10,883 already weeded out.
27450 cleanliness campaigns have been conducted across schools and institutions, actively working towards achieving the Ministry’s targets.

*****

MV/AK

(Release ID: 2065624) Visitor Counter : 39

MIL OSI Asia Pacific News –

January 23, 2025

MIL-OSI Asia-Pac: DARPG Secretary visits Department of Drinking Water and Sanitation, Ministry of Jal Shakti to review SPECIAL CAMPAIGN 4.0

Source: Government of India

Posted On: 17 OCT 2024 10:23AM by PIB Delhi

Special Campaign 4.0 has been launched by Department of Administrative Reforms & Public Grievances (DARPG) for institutionalising Swachhata and minimising pendency in Government offices from 2^nd October to 31^st October, 2024. Department of Drinking Water and Sanitation, along with its Programme Divisions and Dr. Syama Prasad Mookerjee National Institute of Water and Sanitation (SPM-NIWAS) is actively participating in the Special Campaign for Disposal of Pending Matters (SCDPM) 4.0.

Shri V. Srinivas, Secretary, DARPG had fruitful discussion with Ms. Vini Mahajan, Secretary, DDWS during his visit to Pt. Deendayal Antyodaya Bhawan, CGO Complex on 15.10.2024 at 4.30 PM with respect to review of Special Campaign 4.0. Shri Ashok K. K. Meena, OSD, DDWS was also present along with senior officers from both the Departments. Secretary, DARPG also visited the creche in the Pt. Deendayal Antyodaya Bhawan, maintained by DDWS.

Sharing the experience of “Swachhta Hi Sewa 2024”, Campaign, many valuable suggestions were made by Ms. Vini Mahajan, Secretary, DDWS with regard to Special Campaign 4.0 which inter-alia include extension of the Special Campaign beyond Central Govt offices; development of I-GoT module on Swachhta for all sanitation workers; Pension module for all those retiring in the near future; citizen friendly practices in ease of rules and procedures including their accessibility; inclusive measures like setting up of Creche facility; recognizing the efforts of the sanitation workers and honoring them, holding special medical camps for them.

***

DSK

(Release ID: 2065634) Visitor Counter : 64

MIL OSI Asia Pacific News –

January 23, 2025
MIL-OSI United Kingdom: Environment Agency works to preserve North East salmon stocks
Source: United Kingdom – Executive Government & Departments

Atlantic salmon stocks in the Tyne remain buoyant despite stocks across England reaching new lows according to a report released last week (Monday 7 October).
An image of an adult salmon.

Atlantic salmon stocks in the Tyne remain buoyant despite stocks across England reaching new lows according to a report released last week (Monday 7 October).

According to the Atlantic Salmon Stock Assessment for 2024 from the Environment Agency and the Centre for Environment, Fisheries and Aquaculture Science (Cefas), 90% of principal salmon rivers in England are classified as either “at risk” or “probably at risk,” meaning salmon numbers are below minimum levels to support sustainable populations.

However, the River Tyne’s salmon stocks are the only location where they remain “not at risk” and the Coquet and Wear are amongst only three rivers nationally where stocks are deemed to be “probably not at risk”.

The Environment Agency is working with partners to reduce impacts affecting stocks globally, including barriers to migration, water scarcity from abstraction and the persistent challenge from climate change, including warming seas.

The Environment Agency and Natural England are calling on everyone from landowners and farmers to energy, waste and water companies to do more to protect this iconic and pivotal species.

Jon Shelley, Fisheries Technical Specialist at the Environment Agency said:

We are proud that the Salmon Stocks in the Tyne remain “not at risk” and that rivers across the North East are providing a safe haven for salmon.

However, we know the importance of this report and are not complacent in the North East. Action is needed to combat all pressures impacting salmon, to help maintain the salmon stocks in the region and improve the stocks across the country.

We will continue our vital work to help preserve the salmon stocks in our area by working closely with our partners and the community.

Share this page

The following links open in a new tab

Share on Facebook (opens in new tab)

Share on Twitter (opens in new tab)

Updates to this page

Published 17 October 2024
MIL OSI United Kingdom –
January 23, 2025
MIL-OSI USA: FEMA Support For North Carolina Surpasses $100 Million
Source: US Federal Emergency Management Agency

Headline: FEMA Support For North Carolina Surpasses $100 Million

FEMA Support For North Carolina Surpasses $100 Million
More than $100 million in FEMA individual assistance has been approved for North Carolina households affected by Tropical Storm Helene.

North Carolina Recovery By the Numbers

All numbers and dollar amounts are as of close of business Oct. 15.
- FEMA has made individual assistance available to 39 North Carolina counties and tribal members of the Eastern Band of Cherokee Indians.
- FEMA’s Individuals and Households Program has approved over $102 million including:
  
  $18.6 million to help homeowners and renters to pay for emergency home repairs, home replacement or other housing needs.
  
  $83.6 million to help with other serious disaster-related needs, like moving expenses, childcare and disaster-related dental, medical or funeral expenses.
- Disaster Survivor Assistance specialists are in North Carolina communities helping individuals apply for assistance. As of today, these teams have registered more than 5,000 survivors.
- 6 Disaster Recovery Centers are operating in impacted areas, and to-date, have served more than 2,500 visitors. Even more centers will be opening in the coming days.
- FEMA is providing temporary hotel stays to more than 2,000 households through Transitional Sheltering Assistance.
- FEMA inspectors have performed more than 14,400 home inspections.
Disaster Unemployment Assistance is available in eligible, affected counties. For more information on this program visit des.nc.gov/dua or call 919-629-3857 (for Spanish call 919-276-5698).
barbara.murien…
Thu, 10/17/2024 – 11:05

MIL OSI USA News –
January 23, 2025
MIL-OSI Asia-Pac: PRESIDENT OF INDIA VISITED MAURITANIA YESTERDAY

Source: Government of India (2)

PRESIDENT OF INDIA VISITED MAURITANIA YESTERDAY

MET PRESIDENT OF PRESIDENT OF MAURITANIA; LED DELEGATION LEVEL-TALKS

PRESIDENT MURMU ADDRESSED INDIAN COMMUNITY IN MAURITANIA

INDIAN COMMUNITY’S SKILLS, EXPERTISE AND EXPERIENCE MATTER FOR INDIA’S PROGRESS: PRESIDENT MURMU

FOUR MOUS IN THE AREAS OF TRAINING OF DIPLOMATS, CULTURAL EXCHANGE, VISA EXEMPTION AND FOREIGN OFFICE CONSULTATIONS WERE SIGNED AND EXCHANGED

Posted On: 17 OCT 2024 11:12AM by PIB Delhi

The President of India, Smt Droupadi Murmu, was in Mauritania yesterday (October 16, 2024), on the second leg of her State Visits to Algeria, Mauritania, and Malawi. On her arrival at Nouakchott-Oumtounsy Airport, President Droupadi Murmu was warmly received by the President of the Islamic Republic of Mauritania, H.E. Mr Mohamed Ould Ghazouani and accorded a ceremonial welcome. The Prime Minister and cabinet ministers of Mauritania were also present on the occasion.

This is the first visit by an Indian President to Mauritania. The President was accompanied by the Minister of State, Shri Sukanata Majumdar, and Members of Parliament, Shri Mukeshkumar Dalal and Shri Atul Garg .

The President addressed the members of the Indian Community in Mauritania at a Reception hosted by the Ambassador of India to Mauritania.

Addressing the small but vibrant gathering of the Indian community, the President commended the Indian community for contributing significantly to the socio-economic development of Mauritania. She said that their skills, expertise and experience are also important for India’s progress.

The President appreciated the Government and people of Mauritania for supporting the Indian community. She said that because of their inclusive and welcoming spirit, the Indian community in Mauritania is prospering.

After the community reception event, the President visited the Presidential Palace where she held a meeting with President Mohamed Ould Ghazouani of Mauritania. Both leaders discussed ways to further strengthen the relationship between India and Mauritania. Subsequently, they led the delegation-level talk and witnessed the signing and exchange of four MoUs in the areas of training of diplomats, cultural exchange, visa exemption and Foreign Office consultations.

Earlier, the Minister of Foreign Affairs, Cooperation and Mauritanians Abroad of Mauritania, H.E. Mr Mohamed Salem Ould Merzoug called on the President in a separate engagement.

The President left for Malawi – the final leg of her three-nation visit.

Please click here to see the President’s Speech –

***

MJPS/SR

(Release ID: 2065646) Visitor Counter : 26

MIL OSI Asia Pacific News –

January 23, 2025

MIL-OSI Asia-Pac: Department of Animal Husbandry and Dairying progressively achieves targets set under Special Campaign 4.0

Source: Government of India

Department of Animal Husbandry and Dairying progressively achieves targets set under Special Campaign 4.0

Focuses on Public Grievance resolution and cleanliness of office spaces

Posted On: 17 OCT 2024 11:21AM by PIB Delhi

The ongoing Special Campaign 4.0 is being implemented in the Department of Animal Husbandry and Dairying under the leadership of the Minister of Fisheries, Animal Husbandry and Dairying (FAHD) Shri Rajiv Ranjan Singh alias Lalan Singh, Shri. Prof. S P Baghel, Minister of State FAHD and under the overall guidance of Ms. Alka Upadhyaya, Secretary, Department of Animal Husbandry and Dairying(DAHD).

Union Minister Shri Rajiv Ranjan Singh alias Lalan Singh launched the Special Campaign 4.0 at Krishi Bhawan, New Delhi on 2^nd October 2024 in which Secretary, DAHD and all senior officers of the department participated enthusiastically. The field offices of the Department also launched the campaign with full fervor.

With a view to implement the Special Campaign 4.0 in an effective and efficient manner, 9 sub nodal officers were designated in the Department. The Nodal officer of the department has chaired two meetings to finalize and review the progress of the targets for Special Campaign 4.0. The first meeting was held on 23^rd September, 2024 to finalize the targets during the “preparatory phase” of the campaign and the second meeting was held on 16^th October, 2024 to review the mid-campaign achievement/performance vis-à-vis the set targets.

Meeting held with sub nodal officers on 23.09. 2024 Meeting held with sub nodal officers on 16.10. 2024

As per the data entered in Special Campaign 4.0 portal as on 16.10.2024, the status of achievement against the targets are as follows:

		Special Campaign 4.0
Sl. No.	Parameter	Target	Achievement
1.	Reference from MPs	5	5
2.	Parliamentary Assurance	8	0
3.	IMC References (Cabinet Proposals)	0	0
4.	State Govt. References	0	0
5.	Public grievances	197	110
6.	PMO Ref.	2	2
7.	Public grievances Appeal	98	7
8.	Easing of Rules/processes	1	1
9.	Review of Physical files	10244	10244
10	Review of e-files	633	513
11	Cleanliness of sites	213	156

During the current campaign till date INR 8,42,753/- revenue has been generated which is significantly higher compared to the revenue of INR 4,52,213/- generated during the entire Special Campaign 3.0. The Department is committed to achieving the targets set for the Special Campaign 4.0 and will continue to put in the requisite efforts to ensure the timely achievement of the same.

****

(Release ID: 2065651) Visitor Counter : 31

MIL OSI Asia Pacific News –

January 23, 2025

MIL-OSI Economics: How AI is making eyesight-saving care more accessible in resource-constrained settings

Source: Google

Error 404 (Not Found)!!! <a href="https://blog.google/" rel="nofollow"></a> 404. <ins>That’s an error.</ins> The requested URL <code>/around-the-globe/google-asia/how-ai-is-making-eyesight-saving-care-more-accessible-in-resource-constrained-settings/</code> was not found on this server. <ins>That’s all we know.</ins> 

MIL OSI Economics –

January 23, 2025
MIL-OSI: Draganfly to Showcase Latest Drone Innovations at Wings of Saskatchewan in Regina, October 30-31

Source: GlobeNewswire (MIL-OSI)

Advancements in drone technology to be presented at the leading aviation industry event, fostering cross-industry collaboration.

Saskatoon, Sask., Oct. 17, 2024 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading developer of drone solutions and systems, proudly announces its participation in the upcoming Wings of Saskatchewan event in Regina, from October 30 to October 31, 2024. Draganfly will showcase its latest drone technology advancements, contributing to discussions on industry trends, safety, and regulatory considerations alongside key stakeholders in the aviation sector.

The Wings of Saskatchewan Conference, hosted by the Saskatchewan Aerial Applicators Association and the Saskatchewan Aviation Council, serves as a vital gathering for the aviation community. This year’s event will bring together leaders from both civil and commercial aviation sectors to discuss technological advancements, regulatory updates, and future trends within the industry.

Draganfly will emphasize the need for synergy across the aviation industry at the conference by addressing essential topics, including airspace safety and the regulatory challenges impacting the drone sector. This presentation will spotlight the benefits of enhanced communication and collaboration between fixed-wing, helicopter, and RPAS (Remotely Piloted Aircraft Systems) to promote safe, efficient, and integrated airspace management.

“We’re thrilled to be a part of the Wings of Saskatchewan and to share our newest innovations with industry leaders,” said Cameron Chell, CEO of Draganfly. “This event provides a great platform for us to explore key industry trends, discuss airspace safety, and address the regulatory challenges that impact our sector. It also allows us to demonstrate how Draganfly’s technology can foster collaboration across fixed-wing, helicopter, and RPAS industries, transforming operations in challenging environments like those found in Saskatchewan.”

In addition to its presentation, Draganfly will feature its latest UAV systems, including the APEX Drone and the Commander 3XL, known for their versatility, advanced autonomy, and interoperability. Conference attendees will have the opportunity to explore these state-of-the-art technologies firsthand and discover their applications in surveying, environmental monitoring, and search and rescue operations, among other use cases.

About Draganfly Inc.

Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) is a global leader in the UAV and drone solutions space, providing cutting-edge technology for public safety, agriculture, industrial inspection, and mapping and surveying. With over two decades of experience, Draganfly has developed an extensive portfolio of award-winning drone systems and software that continue to set the standard for quality and performance. Draganfly is committed to driving industry advancement through innovation, collaboration, and a steadfast focus on safety.

For more information on Draganfly, please visit us at http://www.draganfly.com. For additional investor information, visit:

Media Contact Email: media@draganfly.com

Company Contact Email: info@draganfly.com

The MIL Network –

January 23, 2025
MIL-OSI: Calian continues to respond to growing demand for global defence solutions

Source: GlobeNewswire (MIL-OSI)

OTTAWA, Ontario, Oct. 17, 2024 (GLOBE NEWSWIRE) — Calian Group Ltd. (TSX: CGY), closed fiscal year 2024 ending September 30, having signed several defence contracts in the fourth quarter valued at approximately $29 million, further solidifying its position as a trusted partner in the global defence industry. These new contracts align with Calian’s mission to equip, prepare and protect military personnel as global military spending continues to surge amid war, geopolitical instability and the heightened need for new and advanced technologies.

Global defence budgets continue to rise and are projected to reach $2.5 trillion by 2028 according to Markets and Markets. Throughout FY2024, Calian continued to win contracts to support key global defence initiatives that enhance military readiness and operational effectiveness. Closing out Q4, Calian was selected to provide Canada and NATO members with operational and training support, defence manufacturing, engineering support and technical expertise.

“As the world faces continued unrest, Calian is more dedicated than ever to delivering cutting-edge defence solutions to ensure the preparedness and safety of Canadian, NATO and allied personnel,” said Kevin Ford, CEO, Calian. “Our recent contract signings reflect the growing trust our global partners place in Calian to support critical global defence initiatives. As we move into FY2025, we remain focused on helping our allies prepare for the complex challenges that lie ahead, equipping them with the tools and expertise needed to safeguard national and global security.”

In a 2024 McKinsey & Company report they indicated that following the invasion of Ukraine, NATO member states have announced plans to spend significantly more on defence in the coming years. It goes on to add that if actual spending stays in line with the latest announcements made by European governments, their analysis estimates that cumulative defence spending could increase by €700 billion to €800 billion between 2022 and 2028, with total European spending reaching as much as €500 billion per year in 2028. With Calian’s recent acquisition of U.K.’s Mabway, combined with its leadership in providing defence readiness expertise for NATO countries, Calian is uniquely positioned going into FY2025 to support these increasing demands.

With over 40 years of experience delivering defence solutions to Canada and its global allies, Calian provides a broad portfolio of services, including military training, simulation, healthcare, cybersecurity and complex systems integration. These recent Q4 contract signings reinforce Calian’s commitment to helping military forces remain ready and resilient in today’s fast-changing security environment.

Learn more about how Calian delivers confidence for military customers, no matter their needs: https://www.calian.com/defence/.

About Calian
http://www.calian.com
We keep the world moving forward. Calian® helps people communicate, innovate, learn and lead safe and healthy lives. Every day, our employees live our values of customer commitment, integrity, innovation, respect and teamwork to engineer reliable solutions that solve complex challenges. That’s Confidence. Engineered. A stable and growing 40-year company, we are headquartered in Ottawa with offices and projects spanning North American, European and international markets. Visit calian.com to learn about innovative healthcare, communications, learning and cybersecurity solutions.

Product or service names mentioned herein may be the trademarks of their respective owners.

Media inquiries:
media@calian.com
613-599-8600 x 2298

Investor Relations inquiries:
ir@calian.com

DISCLAIMER
Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events. Such statements are generally accompanied by words such as “intend”, “anticipate”, “believe”, “estimate”, “expect” or similar statements. Factors which could cause results or events to differ from current expectations include, among other things: the impact of price competition; scarce number of qualified professionals; the impact of rapid technological and market change; loss of business or credit risk with major customers; technical risks on fixed price projects; general industry and market conditions and growth rates; international growth and global economic conditions, and including currency exchange rate fluctuations; and the impact of consolidations in the business services industry. For additional information with respect to certain of these and other factors, please see the Company’s most recent annual report and other reports filed by Calian with the Ontario Securities Commission. Calian disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance can be given that actual results, performance or achievement expressed in, or implied by, forward-looking statements within this disclosure will occur, or if they do, that any benefits may be derived from them.

Calian · Head Office · 770 Palladium Drive · Ottawa · Ontario · Canada · K2V 1C8
Tel: 613.599.8600 · Fax: 613-592-3664 · General info email: info@calian.com

The MIL Network –

January 23, 2025
MIL-OSI: CIB Marine Bancshares, Inc. Announces Final Redemption of Preferred Stock
Source: GlobeNewswire (MIL-OSI)

BROOKFIELD, Wis., Oct. 17, 2024 (GLOBE NEWSWIRE) — CIB Marine Bancshares, Inc. (the “Company” or “CIB Marine”) (OTCQX: CIBH) announces the full and final redemption of all preferred stock pursuant to its Second Amended and Restated Articles of Organization. Effective October 31, 2024, approximately 14,633 of CIB Marine’s Series A Preferred shares and 1,610 of Series B Preferred shares will be redeemed at $825 per share. This redemption is a full redemption of all outstanding preferred stock; there will be no preferred stock remaining in the Company’s capital structure. The $13.4 million redemption will be funded by cash on hand resulting from a distribution from the Company’s wholly-owned subsidiary, CIBM Bank; a distribution from the Company’s non-bank subsidiary, CIB Marine Capital, LLC; and a portion of the $10 million subordinated debt offering completed in the first quarter of 2022. Documentation will be mailed to all preferred shareholders of record by the Company’s redemption agent, Computershare Trust Company, N.A., on or about October 17, 2024.

Mr. J. Brian Chaffin, President and CEO of the Company stated, “The October 31^st redemption of all remaining preferred stock is a great achievement for the Company and all our shareholders. This transaction increases liquidity for the remaining preferred shares and benefits our common shareholders in two ways: by eliminating the potentially dilutive convertible Series B shares and redeeming all outstanding preferred stock at a discounted rate. The $825 per share redemption price is below both its balance sheet carrying value of $850 per share and its liquidation preference value of $1,000 per share.”

In addition, Mr. Mark Elste, Chaiman of the Board of Directors, noted. “This is a significant accomplishment that the Board of Directors and management have been focused on for more than four years. The redemption of all preferred stock simplifies the Company’s capital structure to only one form of equity: common stock with full voting rights. It opens up opportunities to continue building shareholder value, the likes of which have been constrained by the outstanding preferred stock.”

CIB Marine Bancshares, Inc. is the holding company for CIBM Bank, which operates nine banking offices Illinois, Wisconsin, and Indiana, and has mortgage loan officers and/or offices in ten states. More information on the Company is available at http://www.cibmarine.com, including recent shareholder letters, links to regulatory financial reports, and audited financial statements.

FORWARD-LOOKING STATEMENTS
CIB Marine has made statements in this release that may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. CIB Marine intends these forward-looking statements to be subject to the safe harbor created thereby and is including this statement to avail itself of the safe harbor. Forward-looking statements are identified generally by statements containing words and phrases such as “may,” “project,” “are confident,” “should be,” “intend,” “predict,” “believe,” “plan,” “expect,” “estimate,” “anticipate” and similar expressions. These forward-looking statements reflect CIB Marine’s current views with respect to future events and financial performance that are subject to many uncertainties and factors relating to CIB Marine’s operations and the business environment, which could change at any time.

There are inherent difficulties in predicting factors that may affect the accuracy of forward-looking statements.

Stockholders should note that many factors, some of which are discussed elsewhere in this release and in the documents that are incorporated by reference, could affect the future financial results of CIB Marine and could cause those results to differ materially from those expressed in forward-looking statements contained or incorporated by reference in this document. These factors, many of which are beyond CIB Marine’s control, include but are not limited to:
- operating, legal, execution, credit, market, security (including cyber), and regulatory risks;
- economic, political, and competitive forces affecting CIB Marine’s banking business;
- the impact on net interest income and securities values from changes in monetary policy and general economic and political conditions; and
- the risk that CIB Marine’s analyses of these risks and forces could be incorrect and/or that the strategies developed to address them could be unsuccessful.
These factors should be considered in evaluating the forward-looking statements, and undue reliance should not be placed on such statements. Forward-looking statements speak only as of the date they are made. CIB Marine undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Forward-looking statements are subject to significant risks and uncertainties and CIB Marine’s actual results may differ materially from the results discussed in forward-looking statements.

FOR INFORMATION CONTACT:
J. Brian Chaffin, President & CEO
(217) 355-0900
brian.chaffin@cibmbank.com

The MIL Network –
January 23, 2025
MIL-OSI Russia: Artificial Intelligence Transforms Moscow’s Transport and Road Safety
Source: Moscow Department of Transport

The Moscow Department of Transport reported on the main projects related to Artificial Intelligence. From biometric payments to autonomous trams and advanced video analytics, AI-driven innovations are setting new standards in public transportation and traffic management.

Artificial Intelligence Transforms Moscow’s Transport and Road Safety.
- Biometric Payment Revolution
For the past three years, biometric payment technology has been transforming the way people travel in Moscow. Available across all metro stations, Moscow Central Circle (MCC), Aeroexpress, regular river transport, and four Moscow Central Diameters (MCD) stations, this cutting-edge system allows passengers to pass through turnstiles with just a glance—no card or smartphone required.

With bank-level security, this seamless service has already facilitated over 125 million biometric entries, making it one of the most convenient and secure transit payment systems globally.
- Russia’s First Autonomous Tram
Moscow is home to Russia’s first autonomous tram, a breakthrough in public transport innovation. This tram, equipped with a world-first set of technologies, operates without the need for external control systems. Its software, entirely developed by Metro’s in-house team, belongs to the Moscow Government and is unique across Europe.

Since its introduction, the autonomous tram has covered over 1,800 kilometers without a single traffic violation, proving both its reliability and safety on the roads.
- Sphere: The Video Analytics System Safeguarding Moscow
The Sphere video analytics system has been instrumental in enhancing public safety across Moscow. Operational at all metro stations since September 1, 2020, Sphere helps law enforcement detain individuals on wanted lists and locate missing persons, including the elderly and children.

Since its implementation, over 11,000 criminals have been apprehended, and more than 1,500 missing persons, including 300 children, have been located thanks to Sphere.
- Real-Time Monitoring of Metro Carriage Load
To further improve passenger comfort, Moscow’s metro now uses machine learning algorithms to monitor carriage load in real time. The system updates every 10 seconds, factoring in the type and capacity of carriages, major transfer points, and time-specific data. This unique service is available through the Moscow Metro app, offering unparalleled accuracy in carriage load assessments.
- AI-Powered Moscow Transport Contact Center
Since 2019, AI has been assisting passengers via Moscow’s transport contact center (dial 3210). A voice assistant automatically handles calls related to car evacuation, helping streamline operations. The contact center, operational for over 11 years, fields around 6,000 inquiries daily, providing crucial information on public transport, including fare rates, free parking availability, and more.
- Advanced Video Analytics on MKAD and Major Highways
Moscow has installed over 1,500 high-resolution cameras on the MKAD, MCD, and key roads, covering 100% of major routes without blind spots. These cameras detect 13 different types of incidents and send real-time video to the Traffic Management Center within seconds, allowing for rapid response. Thanks to this intelligent system, traffic accidents involving injuries on the MKAD have decreased by 20% over the last three years.
- Leading the World in Photo and Video Traffic Monitoring
With 3,800 cameras monitoring traffic across the city, Moscow’s photo and video recording system is one of the most advanced globally. The system, powered by AI, now detects drivers using phones or not wearing seatbelts, and as of 2023, it can accurately determine whether motorcyclists are wearing helmets and whether passengers are buckled up. AI also enables the detection of more complex violations, such as blocking intersections and failing to yield to pedestrians.
- Smart Intersections Speed Up Traffic
Moscow has introduced over 600 smart intersections equipped with AI-driven traffic lights. These lights adjust in real-time based on road conditions, using data from sensors embedded in the asphalt. As a result, both city and private transport pass through these intersections 25-30% faster, while pedestrians wait 20-25% less for the green signal.

Moscow continues to lead the way in using AI to revolutionize transport and road safety, setting a global standard for innovation in urban mobility. With AI-enhanced systems in place, residents and visitors alike can expect safer, faster, and more convenient journeys across the city.
MIL OSI Russia News –
January 23, 2025

MIL-OSI: Invesco Ltd: Form 8.3 – StoneX Group Inc; Public dealing disclosure

Source: GlobeNewswire (MIL-OSI)

FORM 8.3

PUBLIC DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

KEY INFORMATION

(a)

Full name of discloser:

Invesco Ltd.

(b)

Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c)

Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree

StoneX Group Inc.

(d)

If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e)

Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure

16.10.2024

(f)

In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state “N/A”

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

Common US8618961085

Interests

Short Positions

Number

(1)

Relevant securities owned and/or controlled:

436,273*

1.36

(2)

Cash-settled derivatives:

(3)

Stock-settled derivatives (including options) and agreements to purchase/sell:

Total

436,273*

1.36

*The change in the holding of 838 shares since the last disclosure on 16.10.2024 is due to the transfer out of a discretionary holding at 87.22 USD.

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)

Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)

Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

Common US8618961085

Purchase

88.22 USD

(b)

Cash-settled derivative transactions

Class of relevant security

Product description e.g. CFD

Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c)

Stock-settled derivative transactions (including options)

(i)

Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)

Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)

Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

OTHER INFORMATION

(a)

Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)

Agreements, arrangements, or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”

None

(c)

Attachments

Is a Supplemental Form 8 (Open Positions) attached?

Date of disclosure

17.10.2024

Contact name

Philippa Holmes

Telephone number

+441491417447

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at http://www.thetakeoverpanel.org.uk.

The MIL Network –

January 23, 2025

MIL-OSI: Convex partners with EXL to accelerate operational excellence through data and technology

Source: GlobeNewswire (MIL-OSI)

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) — EXL [NASDAQ: EXLS], a leading data analytics and digital operations and solutions company, was selected by Convex Group Limited (“Convex”), the international specialty insurer and reinsurer, for a multiyear engagement focused on accelerating delivery of its business operations. The program will improve efficiency and customer experience, delivering a more cost-effective, scalable and resilient operating model.

As part of Convex’s strategically differentiated approach to outsourcing, EXL will help deliver the next phase of development in operational excellence and efficiency, enhancing workflows and delivering integrated data-enriched management information, analytics and AI across the breadth of the operating model. This will allow Convex to continue to maintain its client-centric focus and growth momentum while drawing on EXL’s deep expertise in insurance operations and market-proven AI and data capabilities. In addition, EXL’s multi-tower and multi-geography delivery centers and transformation center of excellence will support Convex’s requirements for flexible and adaptable access to evolving skills and resources.

“We are excited to work closely with Convex to evolve their operating model, supporting better business decisions through data and technology while delivering greater scalability and efficiency in their operations,” said Vikas Bhalla, president, EXL and head of Insurance business. “Partnering with EXL will not only support Convex in its continued growth and deployment of current technologies but also help the organization leverage future technological advancements with speed and agility.”

“We selected EXL as a strategic partner because we felt they aligned well with our values while demonstrating a strong capability and drive to leverage cutting-edge technology and data in the delivery of services,” said Adrian Spieler, chief operating officer at Convex. “EXL not only brings the London market experience but also the experience of implementing transformational solutions alongside transparency and high-quality management information into operations. We see this engagement as an accelerator for delivering operational excellence to our brokers and clients.”

EXL works with more than 550 global insurers, re-insurers, brokers and Insurtech firms to leverage data and artificial intelligent based solutions to help our clients improve risk mitigation, reduce indemnity spend, enhance customer experience and lower service costs. With a 25-year heritage in the insurance industry, EXL’s global presence and deep insurance expertise help clients stay resilient and leverage the best-of-breed solutions to stay ahead.

To learn more about EXL’s data-led approach to digital transformation, please visit here.

About EXL
EXL (NASDAQ: EXLS) is a leading data analytics and digital operations and solutions company. We partner with clients using a data and AI-led approach to reinvent business models, drive better business outcomes and unlock growth with speed. EXL harnesses the power of data, analytics, AI, and deep industry knowledge to transform operations for the world’s leading corporations in industries including insurance, healthcare, banking and financial services, media and retail, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have more than 55,000 employees spanning six continents. For more information, visit http://www.exlservice.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL’s operations and business environment, all of which are difficult to predict and many of which are beyond EXL’s control. Forward-looking statements include information concerning EXL’s possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. These statements are based on assumptions that we have made in light of management’s experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although EXL believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect EXL’s actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors, which include our ability to maintain and grow client demand, our ability to hire and retain sufficiently trained employees, and our ability to accurately estimate and/or manage costs, rising interest rates, rising inflation and recessionary economic trends, are discussed in more detail in EXL’s filings with the Securities and Exchange Commission, including EXL’s Annual Report on Form 10-K. You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect EXL. EXL has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.
© 2024 ExlService Holdings, Inc. All rights reserved. For more information go to http://www.exlservice.com/legal-disclaimer

Contacts
Media
Keith Little
+1 703-598-0980
media.relations@exlservice.com

Investor Relations
John Kristoff
+1 212 209 4613
IR@exlservice.com

The MIL Network –

January 23, 2025
MIL-OSI: Banzai Announces Expanded Partnership with Salesforce, Today’s Industry Leading AI CRM Company for Smarter Webinar Campaigns
Source: GlobeNewswire (MIL-OSI)

Simplified Workflows and Real-Time Insights with Account Engagement Integration in Demio Give Salesforce Users the Tools They Need to Enhance Their Webinar Strategy

SEATTLE, Oct. 17, 2024 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced significant enhancements to its Demio platform through deeper integration with Salesforce, the industry leading AI CRM company.

These new features address key operational challenges faced by marketing teams, delivering an improved level of precision in webinar data management, from automated lead capture to real-time UTM tracking. Marketers leveraging this integration will not only see immediate efficiency gains but will also benefit from enhanced decision-making capabilities, thanks to cleaner, more accurate data pipelines.

Key Enhancements Designed to Maximize Efficiency and Insight

This integration addresses common pain points for Salesforce Account Engagement users by automating the syncing of webinar data—from contact information to UTM tracking—greatly reducing the time and effort required for manual processes. Marketers can now focus on optimizing campaigns with real-time insights, enabling data-driven adjustments with speed and precision. The seamless UTM tracking integration offers a comprehensive view of campaign performance across channels, while Demio’s smart list management feature ensures that webinar registrants are automatically added to targeted Salesforce Account Engagement lists, ensuring no lead slips through the cracks.

Key capabilities include:
- Automated List Management: Simplify the process by automatically syncing registrants to Salesforce Account Engagement, ensuring optimal engagement across the funnel.
- Real-Time UTM Tracking: Gain holistic insights into campaign performance with real-time tracking at both session and individual contact levels.
- Advanced Search for List Management: Quickly navigate extensive lists with Demio’s new auto-search feature, saving time and boosting productivity.
- Custom Field Syncing: Ensure accurate and up-to-date information across platforms, enabling targeted segmentation and precision marketing.
Joe Davy, CEO of Banzai, emphasized the power of this upgraded integration: “By deepening our connectivity with Pardot, we’re offering marketers a more scalable, data-rich experience. This isn’t just a product enhancement; it’s a strategy shift that will drive better outcomes with less effort.”

A Future-Focused Solution for Salesforce Customers

Banzai continues to innovate to ensure its solutions meet the evolving needs of marketing teams. By integrating powerful features directly into users’ workflows, this enhancement sets a new standard for what’s possible in webinar campaign management—paving the way for more strategic, data-driven marketing operations.

About Salesforce

Salesforce is the #1 AI CRM, empowering companies to connect with their customers in a whole new way through the power of CRM + AI + Data + Trust on one unified platform: Einstein 1. For more information visit: http://www.salesforce.com.

About Banzai
Banzai is a marketing technology company that provides essential marketing and sales solutions for businesses of all sizes. On a mission to help their customers achieve their mission, Banzai enables companies of all sizes to target, engage, and measure both new and existing customers more effectively. Banzai customers include Square, Hewlett Packard Enterprise, Thermo Fisher Scientific, Thinkific, Doodle and ActiveCampaign, among thousands of others. Learn more at http://www.banzai.io. For investors, please visit https://ir.banzai.io/.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as “believe,” “may,” “will,” “estimate,” “target,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “propose,” “plan,” “project,” “forecast,” “predict,” “potential,” “seek,” “future,” “outlook,” and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, statements regarding Banzai International, Inc.’s (the “Company’s”): future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing, future or ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to the Company’s industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for retaining existing or acquiring new customers, increasing revenue and executing growth initiatives; and product areas of focus and additional products that may be sold in the future. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which the Company operates, customer demand, the financial markets, economic, business and regulatory and other factors, such as the Company’s ability to execute on its strategy. More detailed information about risk factors can be found in the Company’s Annual Report on Form 10-K and the Company’s Quarterly Reports on Form 10-Q under the heading “Risk Factors,” and in other reports filed by the Company, including reports on Form 8-K. The Company does not undertake any duty to update forward-looking statements after the date of this press release.

Investor Relations
Chris Tyson
Executive Vice President
MZ Group – MZ North America
949-491-8235
BNZI@mzgroup.us
http://www.mzgroup.us

Media
Rachel Meyrowitz
Director, Demand Generation, Banzai
media@banzai.io

The MIL Network –
January 23, 2025

MIL-OSI: LM Funding America, Inc.’s Bitcoin Holdings was Valued at $9.6 million in Monthly Update

Source: GlobeNewswire (MIL-OSI)

TAMPA, Fla., Oct. 17, 2024 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a cryptocurrency mining and technology-based specialty finance company, today provided a preliminary, unaudited Bitcoin mining and operational update for the month ended September 30, 2024.

Metrics *	Three Months 1^stQtr. 2024	Three Months 2^ndQtr. 2024	One Month September 30, 2024	Three Months 3^rdQtr. 2024	Nine Months Ended September 30, 2024
Bitcoin Beginning Balance	95.1	163.4	135.7	160.4	95.1
Bitcoin Mined, net	86.4	44.1	6.6	18.4	148.9
Bitcoin Sold	(18.0)	(47.0)	–	(36.5)	(101.5)
Service Fee (rounding)	(0.1)	(0.1)	0.1	–	(0.2)
Bitcoin Holdings at Month End	163.4	160.4	142.3	142.3	142.3

Approximate Miners Deployed at Month End	5,940	5,880	3,700		3,700
Approximate Miners In-Transit at Month End			2,200		2,200
Approximate Potential Hash Rate at Month End (PH/s)	614	639	639		639

*Unaudited

The Company estimates that the value of its 142.3 Bitcoin holdings on September 30, 2024, was approximately $9.6 million, based on an estimated October 16, 2024 BTC price of $67,500.

About LM Funding America
LM Funding America, Inc. (Nasdaq: LMFA), operates as a cryptocurrency mining and specialty finance company. It operates through two segments, Specialty Finance and Mining Operations. The company has approximately 5,880 miners, electrified and actively mining Bitcoin, providing the company with approx. 639 petahash of mining capacity. The company was founded in 2008 and is based in Tampa, Florida. For more information, please visit https://www.lmfunding.com.

Forward-Looking Statements
This press release may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” and “project” and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are not guaranties of future results and conditions but rather are subject to various risks and uncertainties. Some of these risks and uncertainties are identified in the Company’s most recent Annual Report on Form 10-K and its other filings with the SEC, which are available at http://www.sec.gov. These risks and uncertainties include, without limitation, uncertainty created by the risks of entering into and operating in the cryptocurrency mining business, uncertainty in the cryptocurrency mining business in general, problems with hosting vendors in the mining business, the capacity of our Bitcoin mining machines and our related ability to purchase power at reasonable prices, the ability to finance and grow our cryptocurrency mining operations, our ability to acquire new accounts in our specialty finance business at appropriate prices, the potential need for additional capital in the future, changes in governmental regulations that affect our ability to collected sufficient amounts on defaulted consumer receivables, changes in the credit or capital markets, changes in interest rates, and negative press regarding the debt collection industry. The occurrence of any of these risks and uncertainties could have a material adverse effect on our business, financial condition, and results of operations.

Contact:
Crescendo Communications, LLC
Tel: (212) 671-1021
Email: LMFA@crescendo-ir.com

The MIL Network –

January 23, 2025

MIL-OSI: HawkSearch Unveils Enhanced Rapid UI Framework with GenAI-Powered Smart Response

Source: GlobeNewswire (MIL-OSI)

WOBURN, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) — Bridgeline Digital, Inc. (NASDAQ: BLIN), a provider of AI-driven marketing technology, announced a major update to HawkSearch’s Rapid UI Framework, a powerful component-based framework that accelerates the integration of Smart Response into their search interfaces. The new version includes a new component for HawkSearch’s Smart Response, a new GenAI capability to complement Smart Search’s features as announced earlier in the year.

Smart Response, now powered by Generative AI (GenAI), delivers a transformative experience for eCommerce users. It goes beyond traditional search results by enabling interactive conversations, summarizing extensive product information, and comparing items directly within the search interface. With the ability to customize “Agents” to align with brand tone, merchandisers can now fine-tune responses to suit specific customer needs. The updated version has comprehensive documentation and implementation examples available via the HawkSearch Developer Portal.

A customer searching for a laptop on an eCommerce site can now engage with Smart Response to refine their options. By asking follow-up questions or requesting product comparisons, Smart Response provides a concise side-by-side analysis of laptops, highlighting key features like battery life and processor speed, helping the customer make a more informed decision without leaving the search interface.

“The Rapid UI Framework is revolutionizing search technology,” said Ari Kahn, CEO of Bridgeline Digital. “Our customers can quickly develop personalized, engaging search experiences, allowing them to drive conversions and enhance user satisfaction with minimal effort.”

About Bridgeline Digital

Bridgeline helps companies grow online revenue by increasing traffic, conversion rates, and average order value. To learn more, please visit http://www.bridgeline.com.

Contact:
Danielle Colvin
SVP of Marketing
Bridgeline Digital
press@bridgeline.com

The MIL Network –

January 23, 2025
MIL-OSI: Corporate social responsibility: Boralex’s ambitious greenhouse gas emissions reduction targets validated by the Science Based Targets initiative (SBTi)
Source: GlobeNewswire (MIL-OSI)

MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) — Boralex inc. (“Boralex” or the “Company”) (TSX: BLX) is proud to announce that it is one of the few companies in the renewable energy sector to have its greenhouse gas (GHG) emissions reduction targets validated by the Science Based Targets initiative (SBTi). This recognition confirms that Boralex’s commitment to reach net-zero GHG emissions by 2050 across its entire value chain is science-based and aligned with a trajectory to achieve the goals set by the Paris Agreement of limiting global temperature increases to less than 1.5^oC.

“The validation of our targets by the SBTi is perfectly in line with our strategic objective of becoming the reference in corporate social responsibility (CSR) for our partners. Today’s announcement consolidates our leadership role in our industry, reinforces our commitment to produce renewable energy in the best possible way, and resonates with our organizational purpose, which aims to benefit future generations,” said Patrick Decostre, President and CEO of Boralex.

“I’m extremely proud of the monumental work carried out by many Boralex employees in recent years, which today enables us to be among the first companies in our industry to have our targets validated by the SBTi initiative. In addition to representing concrete, ambitious and realistic actions to fight climate change, this commitment shows that we are anticipating market needs, including compliance with upcoming CSR regulatory frameworks,” said Mihaela Stefanov, Senior Vice President, Enterprise Risk Management and Corporate Social Responsibility.

To reach net-zero by 2050, the most ambitious designation available through the SBTi process, Boralex has set near- and long-term targets covering 100% of emissions from its entire value chain (Scope 1, 2 and 3):
- Near-term: By 2030, Boralex is committed to reducing its absolute Scope 1 and 2 emissions by 42% from a base year of 2022, and by 2028, to having 90% of its major component suppliers have science-based reduction targets.
- Long-term: By 2050, Boralex is committed to reducing its absolute Scope 1 and 2 emissions by 90% and its Scope 3 emissions per kWh produced and sold by 97%, from a base year of 2022.
To ensure that every kWh generated and produced is as low-carbon as possible, Boralex relies, among other factors, on the gradual electrification of its vehicle fleet, the consumption of electricity from renewable sources at its sites and buildings, and partnerships with strategic low-carbon suppliers.

The validation of our targets by the SBTi, a reputable global organization supported by 130 specialists based in North America and Europe, is a central element in our overall CSR and risk management strategy. Indeed, it was essential for Boralex to go beyond a GHG emissions reduction objective by adopting an action plan to achieve this objective that is concrete, realistic and backed by a recognized authority. For more details on our CSR commitments and actions, visit the Boralex website.

About Boralex

At Boralex, we have been providing affordable renewable energy accessible to everyone for over 30 years. As a leader in the Canadian market and France’s largest independent producer of onshore wind power, we also have facilities in the United States and development projects in the United Kingdom. Over the past five years, our installed capacity has more than doubled to over 3 GW. We are developing a portfolio of more than 6.8 GW in wind, solar projects and storage projects, guided by our values and our corporate social responsibility (CSR) approach. Through profitable and sustainable growth, Boralex is actively participating in the fight against global warming. Thanks to our fearlessness, our discipline, our expertise and our diversity, we continue to be an industry leader. Boralex’s shares are listed on the Toronto Stock Exchange under the ticker symbol BLX.

For more information, visit boralex.com or sedarplus.com. Follow us on Facebook, Twitter, LinkedIn and Instagram.

For more information

Source: Boralex inc.

The MIL Network –
January 23, 2025
MIL-OSI Canada: Statement by the Prime Minister on the International Day for the Eradication of Poverty

Source: Government of Canada – Prime Minister

The Prime Minister, Justin Trudeau, today issued the following statement on the International Day for the Eradication of Poverty:

“Today, on the International Day for the Eradication of Poverty, we stand united to build a world where poverty is not just reduced, but eradicated. A world where every person has the chance to live in dignity, security, and comfort.

“Reducing poverty and inequality across the country starts with building more affordable housing. Earlier this year, we launched our ambitious Housing Plan, which is helping build more affordable homes, faster, and addressing chronic homelessness, especially in underserved communities. Since 2019, the Reaching Home program has supported thousands of projects that have helped over 87,600 people across the country find a stable home and over 148,500 others receive homelessness prevention services, such as short-term rental assistance or help settling disputes with landlords.

“The Canadian Dental Care Plan is helping millions of uninsured Canadians access affordable dental care – and 750,000 people have already received care. Our new National School Food Program will be getting healthy school meals to kids. This Friday, parents across the country will see the monthly Canada Child Benefit payment in their bank accounts. The program – which has lifted hundreds of thousands of kids out of poverty – puts money back in the pockets of Canadians. And with initiatives like $10-a-day child care and the upcoming Canada Disability Benefit, we’re making sure Canadians have the extra savings they need for the things that matter most.

“Our commitment extends beyond our borders as well. Canada’s leadership includes our Poverty Reduction Strategy and Feminist International Assistance Policy, our commitment to advancing the 2030 Agenda for Sustainable Development, and most recently, the adoption of the Pact for the Future last month at the Summit of the Future. Just this year, we contributed nearly $1.3 billion to the International Monetary Fund’s Poverty Reduction and Growth Trust to lift countries out of poverty and make the world a better place.

“Canada is steadfast in its commitment to building a future where poverty is eradicated and where every generation is given a fair chance to succeed.”

MIL OSI Canada News –

January 23, 2025
MIL-OSI: Richtech Robotics Expands Agreement with Ghost Kitchens to Manage 20 Additional Walmart-Located Restaurants, Growing its Restaurant Operations Model

Source: GlobeNewswire (MIL-OSI)

Company’s subsidiary, AlphaMax Management LLC, will optimize operations through the use of robotics and AI cloud technology at restaurants across Arizona, Colorado, and Texas

LAS VEGAS, Oct. 17, 2024 (GLOBE NEWSWIRE) — Richtech Robotics Inc. (Nasdaq: RR) (“Richtech Robotics” or the “Company”), a Nevada-based provider of AI-driven service robots, today announces that it is expanding its restaurant operations model with the signing of a binding Letter of Intent (LOI) with Ghost Kitchens America. Under the terms of the LOI, Richtech Robotics agreed to enter into a franchise agreement with Ghost Kitchens America, pursuant to which the Company will acquire exclusive rights to operate 20 Walmart-located restaurants in Arizona, Colorado, and Texas. These restaurants will be directly managed by Richtech Robotics’ subsidiary, AlphaMax Management LLC, with the aim of optimizing restaurant operations through robotics and AI cloud technology. Each location is expected to generate between $700 thousand and $2 million in annual revenue.

Richtech Robotics is deploying its proprietary automation to enhance operational efficiency, augment and personalize customer experiences, and lower operational costs. The establishment and ongoing management of these restaurants is anticipated to provide a clear, repeatable operational blueprint that businesses can use to scale robotic deployment and optimize their business model.

Matt Casella, President of Richtech Robotics, stated: “Richtech Robotics is committed to the commercialization of robotics, through both robotic sales and the operation of our own robot-powered restaurants. This agreement will significantly add to our restaurant portfolio, and these high-traffic locations will bring greater visibility to our brand and our solutions. Our restaurant operations will showcase the very same robotic and AI platforms offered through our RaaS (Robotics-as-a-Service) business model. We expect these platforms to become a fast-growing and stable revenue stream for us as we leverage them to manage thousands, and eventually tens of thousands, of restaurant operations in the future.”

George Kottas, CEO of Ghost Kitchens America, commented: “All Walmart locations where we’ve signed agreements with Richtech Robotics have strong sales numbers and steady customer traffic. Based on our previous collaborations, Ghost Kitchens is confident that Richtech Robotics’ robotic technology and operational management services will maximize the performance of these restaurants. We look forward to further expanding our partnership with Richtech Robotics as we rapidly grow our restaurant footprint.”

In addition to today’s announcement, the Company has already secured exclusive operational rights for the Ghost Kitchen at a Walmart location in Rockford, Illinois. Additionally, Richtech Robotics has signed a franchise agreement for another Walmart restaurant in Peachtree, Georgia, which is expected to begin operations later this year.

Through AlphaMax Management LLC, Richtech Robotics is operating these restaurants and advancing the application of robotic technology in the food service industry, with the goal of helping businesses reduce costs and improve efficiency.

About Richtech Robotics

Richtech Robotics is a provider of collaborative robotic solutions specializing in the service industry, including the hospitality and healthcare sectors. Our mission is to transform the service industry through collaborative robotic solutions that enhance the customer experience and empower businesses to achieve more. By seamlessly integrating cutting-edge automation, we aspire to create a landscape of enhanced interactions, efficiency, and innovation, propelling organizations toward unparalleled levels of excellence and satisfaction. Learn more at http://www.RichtechRobotics.com and connect with us on X (Twitter), LinkedIn, and YouTube.

About Ghost Kitchens International (GKI)

With restaurants across Canada and the US, GKI is expanding to open 240 new restaurants under the ONE KITCHEN banner in USA and Canada. Each restaurant features multiple national brands made to order, a single operator, innovative front and back-of-house technology, and walk-in and delivery customers. For more information go to http://www.ghostkitchenbrands.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Such forward-looking statements include, but are not limited to, statements regarding the anticipated success and benefits of the partnership with Ghost Kitchens America, including the ability of each location to generated expected annual revenue.

These forward-looking statements are based on Richtech Robotics’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements include, among others, risks and uncertainties related to the parties’ ability to negotiate and execute a definitive agreement in connection with the LOI; Richtech Robotics’ ability to implement the definitive agreement; the ability of each location to generated the expected amount of annual revenue; and Richtech Robotics’ ability to realize the benefits described herein. Investors should read the risk factors set forth in Richtech Robotics’ Annual Report on Form 10-K/A, filed with the SEC on March 27, 2024, the Registration Statement and periodic reports filed with the SEC on or after the date thereof. All of Richtech Robotics’ forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. New risks and uncertainties arise over time, and it is not possible for Richtech Robotics to predict those events or how they may affect Richtech Robotics. If a change to the events and circumstances reflected in Richtech Robotics’ forward-looking statements occurs, Richtech Robotics’ business, financial condition and operating results may vary materially from those expressed in Richtech Robotics’ forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and Richtech Robotics assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Investors:
CORE IR
Matt Blazei
ir@richtechrobotics.com

Media:
Timothy Tanksley
Director of Marketing
Richtech Robotics, Inc
press@richtechrobotics.com
702-534-0050

The MIL Network –

January 23, 2025
MIL-OSI: Astronaut Tim Peake to Headline Timeline’s Adviser 3.0 Conference 2025

Source: GlobeNewswire (MIL-OSI)

LONDON, Oct. 17, 2024 (GLOBE NEWSWIRE) — Timeline is thrilled to announce the return of its flagship event, Adviser 3.0, on 15th May 2025 at Magazine London. This high-energy conference, designed to inspire and equip financial planners with actionable insights, will feature Major Tim Peake, renowned astronaut, as the headline speaker. He will be joined by industry heavyweights, including US leading expert on psychology of financial planning, Dr Meghaan Lurtz, together with sector experts Abraham Okusanya and Brett Davidson and a host of others.

Attendees will have the chance to tailor their experience with over 20 varied sessions spread across five stages. The conference will tackle cutting-edge themes in financial planning such as technology, artificial intelligence, growth and profitability, wealth transfer, succession planning, client communications, leadership, marketing, and the economy. These topics will have practitioners at their core, ensuring content is relevant and applicable to today’s advisory firms.

Adding a burst of colour and energy, the conference’s vibrant Rio Carnival theme will set the stage for a day filled with valuable insights, networking opportunities, and delicious food. The programme will run from 9:00am to 5:30pm, followed by a networking drinks reception and an unforgettable after-party that will carry on until 10:00 pm.

Abraham Okusanya, CEO of Timeline and host of Adviser 3.0, shares his excitement: “We are thrilled to present such a rich and diverse line-up of speakers to the UK advice community. Major Tim Peake’s experiences are truly inspirational, and his insights will beautifully complement the practical sessions we have planned. After two years of learning and fine-tuning, we’re confident this year’s event will exceed all expectations. Tickets are on sale now – they won’t last, so don’t miss out on being part of something amazing.”

For more information and to secure tickets, visit the Adviser 3.0 website.

The MIL Network –

January 23, 2025

Blog

Share this page

Updates to this page

North Carolina Recovery By the Numbers

PRESIDENT OF INDIA VISITED MAURITANIA YESTERDAYMET PRESIDENT OF PRESIDENT OF MAURITANIA; LED DELEGATION LEVEL-TALKS

Department of Animal Husbandry and Dairying progressively achieves targets set under Special Campaign 4.0Focuses on Public Grievance resolution and cleanliness of office spaces

PRESIDENT OF INDIA VISITED MAURITANIA YESTERDAY

MET PRESIDENT OF PRESIDENT OF MAURITANIA; LED DELEGATION LEVEL-TALKS

Department of Animal Husbandry and Dairying progressively achieves targets set under Special Campaign 4.0

Focuses on Public Grievance resolution and cleanliness of office spaces